Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:24PM ET
1.28
Dollar change
-0.08
Percentage change
-5.86
%
IndexRUT P/E- EPS (ttm)-0.74 Insider Own1.51% Shs Outstand192.74M Perf Week-11.99%
Market Cap247.67M Forward P/E- EPS next Y-0.90 Insider Trans-1.31% Shs Float189.83M Perf Month-23.51%
Income-91.17M PEG- EPS next Q-0.45 Inst Own67.23% Short Float17.93% Perf Quarter-8.21%
Sales21.73M P/S11.40 EPS this Y10.66% Inst Trans7.50% Short Ratio3.43 Perf Half Y-58.01%
Book/sh2.08 P/B0.62 EPS next Y45.82% ROA-16.08% Short Interest34.04M Perf Year-70.25%
Cash/sh0.95 P/C1.35 EPS next 5Y45.80% ROE-47.81% 52W Range0.88 - 5.53 Perf YTD-6.88%
Dividend Est.- P/FCF- EPS past 5Y15.14% ROI-20.06% 52W High-76.76% Beta0.77
Dividend TTM- Quick Ratio1.42 Sales past 5Y-29.98% Gross Margin-15.86% 52W Low46.19% ATR (14)0.16
Dividend Ex-Date- Current Ratio1.55 EPS Y/Y TTM87.79% Oper. Margin-1523.91% RSI (14)46.45 Volatility11.38% 12.49%
Employees323 Debt/Eq1.36 Sales Y/Y TTM322.60% Profit Margin-419.62% Recom2.79 Target Price5.22
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q29.93% Payout- Rel Volume0.52 Prev Close1.37
Sales Surprise-53.53% EPS Surprise-2.77% Sales Q/Q17353.52% EarningsMar 26 BMO Avg Volume9.91M Price1.28
SMA20-8.69% SMA502.58% SMA200-52.34% Trades Volume4,740,640 Change-5.86%
Date Action Analyst Rating Change Price Target Change
Dec-11-23Downgrade HSBC Securities Hold → Reduce
Dec-08-23Upgrade Morgan Stanley Underweight → Equal-Weight $3 → $7
Oct-17-23Initiated Cantor Fitzgerald Neutral
Sep-06-23Initiated HSBC Securities Buy $4.21
Jul-19-23Upgrade BofA Securities Neutral → Buy $6 → $10
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Aug-02-22Upgrade Raymond James Mkt Perform → Outperform $8
Mar-27-24 11:37AM
10:00AM
Mar-26-24 07:01AM
Mar-25-24 04:05PM
Mar-19-24 07:44AM
06:05PM Loading…
Mar-18-24 06:05PM
08:00AM
Mar-13-24 07:50AM
Mar-11-24 08:00AM
Mar-05-24 06:56PM
Jan-27-24 07:28AM
05:27AM
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
07:15AM Loading…
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
01:54PM
Dec-19-23 09:41PM
Dec-18-23 04:01PM
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
01:01PM Loading…
01:01PM
12:35PM
Dec-07-23 11:30AM
08:45AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
Nov-08-23 03:39PM
Nov-07-23 05:18PM
08:00AM
07:46AM
07:27AM
07:00AM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
05:14AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
07:18AM
07:00AM
07:00AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
07:45AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
07:00AM
Apr-27-23 04:05PM
Apr-24-23 03:49PM
07:30AM
Apr-13-23 02:17PM
Apr-06-23 10:15AM
08:00AM
06:30AM
Apr-02-23 09:15AM
Mar-30-23 01:54PM
Mar-29-23 08:15AM
07:00AM
Feb-24-23 10:00AM
Feb-08-23 08:05AM
Feb-03-23 05:00AM
Jan-30-23 09:12AM
Jan-24-23 08:58AM
Jan-22-23 09:00AM
Jan-18-23 08:00PM
09:12AM
06:43AM
Jan-09-23 07:00AM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Obenshain AndrewPresident and CEOMar 04 '24Sale1.536,0959,311279,998Mar 05 05:40 PM
Klima Thomas JSee RemarksMar 04 '24Sale1.534,5736,986124,840Mar 05 05:39 PM
Colvin Richard AChief Medical OfficerMar 01 '24Sale1.536,77010,342118,368Mar 05 05:40 PM
Vittiglio JosephChief Business & Legal OfficerFeb 05 '24Sale0.905,2174,70844,783Feb 06 04:07 PM
Klima Thomas JSee RemarksFeb 05 '24Sale0.902,7142,449129,413Feb 06 04:07 PM
Obenshain AndrewPresident and CEOFeb 05 '24Sale0.901,8791,696286,093Feb 06 04:07 PM
Obenshain AndrewPresident and CEOJan 05 '24Sale1.433,1624,520287,972Jan 09 04:05 PM
Colvin Richard AChief Medical OfficerJan 05 '24Sale1.42597845125,138Jan 09 04:05 PM
Krawtschuk ChristopherChief Financial OfficerDec 06 '23Sale4.524,52620,43745,474Dec 08 04:42 PM
Obenshain AndrewPresident and CEONov 03 '23Sale3.178072,555291,134Nov 03 04:10 PM
Colvin Richard AChief Medical OfficerNov 02 '23Sale2.982,3436,975125,735Nov 03 04:10 PM
Klima Thomas JSee RemarksSep 05 '23Sale3.799223,493132,127Sep 06 04:30 PM
Obenshain AndrewPresident and CEOAug 10 '23Sale3.5416,92959,956291,941Aug 10 05:00 PM
Klima Thomas JSee RemarksJun 02 '23Sale3.504,13014,451133,049Jun 06 04:06 PM
Last Close
Mar 28 03:24PM ET
69.90
Dollar change
+3.02
Percentage change
4.52
%
EXAS Exact Sciences Corp. daily Stock Chart
Index- P/E- EPS (ttm)-1.14 Insider Own1.04% Shs Outstand181.36M Perf Week12.74%
Market Cap12.69B Forward P/E562.98 EPS next Y0.12 Insider Trans-5.72% Shs Float179.64M Perf Month24.13%
Income-204.15M PEG- EPS next Q-0.48 Inst Own90.12% Short Float3.63% Perf Quarter-7.64%
Sales2.50B P/S5.08 EPS this Y21.81% Inst Trans-1.74% Short Ratio3.35 Perf Half Y3.62%
Book/sh17.34 P/B4.03 EPS next Y114.05% ROA-3.00% Short Interest6.52M Perf Year5.45%
Cash/sh4.28 P/C16.32 EPS next 5Y- ROE-6.60% 52W Range56.05 - 100.77 Perf YTD-5.52%
Dividend Est.- P/FCF397.40 EPS past 5Y4.59% ROI-3.63% 52W High-30.63% Beta1.24
Dividend TTM- Quick Ratio2.07 Sales past 5Y43.88% Gross Margin70.14% 52W Low24.71% ATR (14)2.68
Dividend Ex-Date- Current Ratio2.32 EPS Y/Y TTM67.92% Oper. Margin-12.20% RSI (14)70.24 Volatility3.75% 4.28%
Employees6600 Debt/Eq0.82 Sales Y/Y TTM19.93% Profit Margin-8.17% Recom1.32 Target Price89.78
Option/ShortYes / Yes LT Debt/Eq0.79 EPS Q/Q61.80% Payout- Rel Volume2.48 Prev Close66.88
Sales Surprise1.26% EPS Surprise36.16% Sales Q/Q16.98% EarningsFeb 21 AMC Avg Volume1.95M Price69.90
SMA2015.10% SMA5013.13% SMA200-4.06% Trades Volume4,406,406 Change4.52%
Date Action Analyst Rating Change Price Target Change
Jan-02-24Upgrade The Benchmark Company Hold → Buy $91
Dec-14-23Initiated Guggenheim Buy $90
Dec-13-23Initiated Wolfe Research Outperform $95
Oct-10-23Upgrade Piper Sandler Neutral → Overweight $90
Sep-28-23Initiated Bernstein Outperform $83
Aug-02-23Downgrade The Benchmark Company Buy → Hold
May-10-23Upgrade Craig Hallum Hold → Buy $55 → $85
May-05-23Initiated UBS Neutral $73
Mar-09-23Upgrade Citigroup Neutral → Buy $70 → $90
Feb-10-23Downgrade Credit Suisse Outperform → Neutral $50 → $70
Today 06:00AM
Mar-27-24 08:05AM
Mar-25-24 09:55AM
Mar-22-24 11:30AM
Mar-18-24 08:19AM
04:30AM Loading…
04:30AM
Mar-14-24 04:16PM
Mar-13-24 05:03PM
Mar-11-24 12:59AM
Mar-08-24 09:55AM
Mar-07-24 07:59AM
Mar-04-24 11:52PM
03:49PM
10:38AM
Mar-03-24 10:32AM
06:00AM Loading…
Feb-26-24 06:00AM
Feb-23-24 12:01PM
Feb-22-24 11:08AM
10:30AM
10:22AM
01:30AM
12:06AM
Feb-21-24 06:20PM
05:41PM
05:12PM
04:05PM
Feb-20-24 02:39AM
Feb-15-24 07:47AM
Feb-14-24 10:00AM
Feb-13-24 08:12PM
05:06PM Loading…
Feb-10-24 05:06PM
Feb-07-24 09:00AM
Feb-01-24 06:00AM
Jan-28-24 09:25AM
Jan-22-24 08:00AM
Jan-18-24 05:04AM
Jan-13-24 02:05PM
Jan-08-24 02:48PM
Jan-07-24 04:30PM
Jan-02-24 06:00AM
Dec-21-23 09:43AM
Dec-20-23 01:49PM
Dec-17-23 05:43AM
Dec-14-23 04:02AM
Dec-13-23 12:52PM
08:45AM
Dec-07-23 08:05AM
Dec-05-23 09:11AM
Dec-04-23 12:13PM
Dec-01-23 11:32AM
05:26AM
Nov-30-23 04:05PM
Nov-25-23 09:45AM
Nov-23-23 12:02PM
Nov-20-23 03:06PM
09:55AM
07:30AM
Nov-17-23 08:04PM
07:10AM
Nov-14-23 05:20AM
Nov-10-23 07:00AM
Nov-09-23 08:10PM
Nov-06-23 09:35AM
Nov-03-23 08:09PM
Nov-02-23 07:23PM
04:02PM
11:03AM
09:40AM
01:14AM
12:30AM
Nov-01-23 06:06PM
04:05PM
06:00AM
Oct-31-23 05:20PM
11:25AM
Oct-30-23 10:20PM
Oct-27-23 08:11PM
Oct-26-23 10:02AM
Oct-25-23 10:02AM
Oct-23-23 08:52PM
Oct-22-23 03:00PM
Oct-20-23 06:08PM
Oct-19-23 02:28PM
09:49AM
Oct-16-23 10:08AM
Oct-12-23 06:00AM
Oct-11-23 08:23AM
Oct-10-23 12:18PM
09:32AM
01:16AM
Oct-09-23 06:00AM
05:58AM
Oct-08-23 07:30AM
Oct-03-23 11:11AM
09:40AM
Oct-02-23 10:45AM
Sep-29-23 09:01PM
Sep-27-23 09:45AM
Sep-22-23 11:28AM
Sep-12-23 08:35AM
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Conroy Kevin TPresident and CEOMar 01 '24Sale59.328,271490,6361,299,496Mar 04 08:38 PM
LEVANGIE DANIEL JDirectorMar 01 '24Sale57.505,000287,50022,975Mar 04 08:42 PM
Cunningham EverettChief Commercial OfficerMar 01 '24Sale59.322,412143,08046,179Mar 04 08:38 PM
Elliott Jeffrey ThomasChief Financial OfficerMar 01 '24Sale59.322,412143,08010,933Mar 04 08:40 PM
Baranick BrianGen. Mgr., Precision OncologyMar 01 '24Sale59.322,323137,80014,095Mar 04 08:36 PM
ORVILLE JACOB AGeneral Manager, ScreeningMar 01 '24Sale59.322,154127,77514,324Mar 04 08:42 PM
Doyle James EdwardDirectorMar 01 '24Sale57.502,000115,00050,110Mar 04 08:39 PM
Condella SarahEVP, Human ResourcesMar 01 '24Sale59.321,724102,26875,787Mar 04 08:37 PM
Herriott JamesGeneral CounselMar 01 '24Sale59.3286251,1349,125Mar 04 08:41 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 29 '24Option Exercise0.005,291013,345Mar 04 08:40 PM
Cunningham EverettChief Commercial OfficerFeb 29 '24Option Exercise0.005,291048,591Mar 04 08:38 PM
Conroy Kevin TPresident and CEOFeb 29 '24Option Exercise0.0018,14301,307,767Mar 04 08:38 PM
Baranick BrianGen. Mgr., Precision OncologyFeb 29 '24Option Exercise0.004,724016,418Mar 04 08:36 PM
Herriott JamesGeneral CounselFeb 29 '24Option Exercise0.001,89009,987Mar 04 08:41 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 29 '24Option Exercise0.004,724016,478Mar 04 08:42 PM
Condella SarahEVP, Human ResourcesFeb 29 '24Option Exercise0.003,779077,511Mar 04 08:37 PM
Conroy Kevin TPresident and CEOFeb 27 '24Sale56.896,263356,3021,289,624Feb 28 07:35 PM
Cunningham EverettChief Commercial OfficerFeb 27 '24Sale56.893,648207,53543,300Feb 28 07:37 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27 '24Sale56.892,710154,1728,054Feb 28 07:36 PM
Baranick BrianGen. Mgr., Precision OncologyFeb 27 '24Sale56.892,027115,31611,694Feb 28 07:34 PM
Condella SarahEVP, Human ResourcesFeb 27 '24Sale56.891,880106,95373,732Feb 28 07:35 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 27 '24Sale56.891,879106,89611,754Feb 28 07:38 PM
Herriott JamesGeneral CounselFeb 27 '24Sale56.8978444,6028,097Feb 28 07:38 PM
Cunningham EverettChief Commercial OfficerFeb 26 '24Option Exercise0.007,678046,948Feb 28 07:37 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 26 '24Option Exercise0.003,954013,633Feb 28 07:38 PM
Herriott JamesGeneral CounselFeb 26 '24Option Exercise0.001,64808,881Feb 28 07:38 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 26 '24Option Exercise0.005,701010,764Feb 28 07:36 PM
Condella SarahEVP, Human ResourcesFeb 26 '24Option Exercise0.003,954075,612Feb 28 07:35 PM
Conroy Kevin TPresident and CEOFeb 26 '24Option Exercise0.0013,18101,295,887Feb 28 07:35 PM
Baranick BrianGen. Mgr., Precision OncologyFeb 26 '24Option Exercise0.003,954013,721Feb 28 07:34 PM
Conroy Kevin TPresident and CEOFeb 23 '24Option Exercise13.96102,8371,435,6051,344,266Feb 26 05:00 PM
Condella SarahEVP, Human ResourcesFeb 23 '24Sale59.721,02160,97471,658Feb 26 05:00 PM
Conroy Kevin TPresident and CEOFeb 22 '24Sale59.7811,565691,3561,241,429Feb 23 07:59 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 22 '24Sale59.781,35180,7635,063Feb 23 08:01 PM
Cunningham EverettChief Commercial OfficerFeb 22 '24Sale59.781,35080,70339,270Feb 23 08:00 PM
Baranick BrianGen. Mgr., Precision OncologyFeb 22 '24Sale59.781,09365,3409,767Feb 23 07:57 PM
Condella SarahEVP, Human ResourcesFeb 22 '24Sale59.781,01360,55772,679Feb 23 07:57 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 22 '24Sale59.781,01360,5579,679Feb 23 08:03 PM
COWARD D SCOTTDirectorFeb 22 '24Sale59.7866339,63444,493Feb 23 07:59 PM
Herriott JamesGeneral CounselFeb 22 '24Sale59.7829117,3967,233Feb 23 08:02 PM
Conroy Kevin TPresident and CEOFeb 21 '24Sale61.504,975305,9621,229,756Feb 22 07:37 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 21 '24Sale61.501,49391,8203,703Feb 22 07:38 PM
Condella SarahEVP, Human ResourcesFeb 21 '24Sale61.501,07966,35871,658Feb 22 07:36 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 21 '24Sale61.501,07866,2978,658Feb 22 07:40 PM
Baranick BrianGen. Mgr., Precision OncologyFeb 21 '24Sale61.5089555,0428,826Feb 22 07:36 PM
COWARD D SCOTTDirectorFeb 21 '24Sale61.5070643,41943,122Feb 22 07:38 PM
Herriott JamesGeneral CounselFeb 21 '24Sale61.5041525,5226,943Feb 22 07:39 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 20 '24Option Exercise0.003,11205,196Feb 22 07:38 PM
Conroy Kevin TPresident and CEOFeb 20 '24Option Exercise0.0010,37401,234,731Feb 22 07:37 PM
COWARD D SCOTTDirectorFeb 20 '24Option Exercise0.002,248043,828Feb 22 07:38 PM
Baranick BrianGen. Mgr., Precision OncologyFeb 20 '24Option Exercise0.001,72909,721Feb 22 07:36 PM
Condella SarahEVP, Human ResourcesFeb 20 '24Option Exercise0.002,248072,737Feb 22 07:36 PM
Herriott JamesGeneral CounselFeb 20 '24Option Exercise0.0086407,358Feb 22 07:39 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 20 '24Option Exercise0.002,24809,736Feb 22 07:40 PM
Conroy Kevin TPresident and CEOFeb 15 '24Sale61.4314,791908,6111,224,357Feb 16 06:22 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 15 '24Sale61.431,888115,9802,084Feb 16 06:24 PM
COWARD D SCOTTDirectorFeb 15 '24Sale61.431,37684,52841,580Feb 16 06:23 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 15 '24Sale61.4396659,3417,488Feb 16 06:26 PM
Condella SarahEVP, Human ResourcesFeb 15 '24Sale61.4396559,28070,489Feb 16 06:21 PM
Herriott JamesGeneral CounselFeb 15 '24Sale61.4342125,8626,494Feb 16 06:25 PM
Conroy Kevin TPresident and CEOFeb 14 '24Option Exercise0.0031,13301,239,148Feb 16 06:22 PM
ORVILLE JACOB AGeneral Manager, ScreeningFeb 14 '24Option Exercise0.002,03108,454Feb 16 06:26 PM
Herriott JamesGeneral CounselFeb 14 '24Option Exercise0.0088306,915Feb 16 06:25 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 14 '24Option Exercise0.003,97203,972Feb 16 06:24 PM
COWARD D SCOTTDirectorFeb 14 '24Option Exercise0.003,972042,956Feb 16 06:23 PM
Condella SarahEVP, Human ResourcesFeb 14 '24Option Exercise0.002,031071,454Feb 16 06:21 PM
Condella SarahEVP, Human ResourcesJan 02 '24Sale73.502,000147,00069,423Jan 04 05:19 PM
Baranick BrianGen. Mgr., Precision OncologyJan 02 '24Sale73.5087964,6067,992Jan 04 05:17 PM
Condella SarahEVP, Human ResourcesDec 14 '23Sale70.002,000140,00071,423Dec 18 07:49 PM
Cunningham EverettChief Commercial OfficerOct 12 '23Sale66.4913,007864,83537,909Oct 13 07:59 PM
Cunningham EverettChief Commercial OfficerOct 11 '23Option Exercise0.0027,504050,916Oct 13 07:59 PM
Condella SarahEVP, Human ResourcesSep 01 '23Sale84.364,500379,62075,814Sep 06 04:04 PM
Elliott Jeffrey ThomasChief Financial OfficerAug 21 '23Sale82.9230,2102,505,0130Aug 23 04:08 PM
Baranick BrianGen. Mgr., Precision OncologyAug 07 '23Sale85.041,350114,8048,871Aug 08 04:09 PM
Baranick BrianGen. Mgr., Precision OncologyAug 04 '23Option Exercise0.002,712010,221Aug 08 04:09 PM
Doyle James EdwardDirectorJul 27 '23Sale97.422,000194,84052,110Jul 28 04:06 PM
Herriott JamesGeneral CounselJul 19 '23Sale100.001,300130,0005,964Jul 21 04:04 PM
Zanotti Katherine SDirectorJun 09 '23Sale90.513,027273,97464,629Jun 12 04:17 PM
Doyle James EdwardDirectorJun 09 '23Sale90.511,402126,89554,110Jun 12 04:29 PM
Herriott JamesGeneral CounselJun 08 '23Sale90.001,300117,0007,264Jun 12 04:14 PM
Doyle James EdwardDirectorMay 26 '23Sale80.622,000161,24051,913May 31 04:13 PM
Condella SarahEVP, Human ResourcesMay 10 '23Sale80.006,087486,96080,314May 12 04:11 PM
ORVILLE JACOB AGeneral Manager, ScreeningMay 10 '23Sale80.005,000400,0006,423May 12 04:09 PM
Herriott JamesGeneral CounselMay 10 '23Sale79.851,300103,8058,564May 12 04:07 PM
Condella SarahEVP, Human ResourcesMay 01 '23Sale63.781,00063,78086,401May 03 04:04 PM
Condella SarahEVP, Human ResourcesApr 03 '23Sale67.191,00067,19086,692Apr 05 04:10 PM